Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation
aDepartment of Cardiology, Daping Hospital, the Third Military Medical University (Army Medical University), Chongqing 400042, China
bKey Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Ministry of Education of China, Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing 400042, China
cDepartment of Cardiovascular Medicine, the General Hospital of Western Theater Command, Chengdu 610083, China
dDivision of Renal Diseases and Hypertension, the George Washington University School of Medicine and Health Sciences, Washington, DC 20541, USA
eState Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, the Third Military Medical University, Chongqing 400042, China
fCardiovascular Research Center of Chongqing College, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Chongqing 400042, China
gDepartment of Cardiology, the First Affiliated Hospital of Kunming Medical University, Kunming 650000, China
* Corresponding authors.
收起